Suppliers and packagers for sernivo

sernivo

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079	NDA	Primus Pharmaceuticals, Inc.	68040-714-08	1 BOTTLE, SPRAY in 1 CARTON (68040-714-08) / 10 g in 1 BOTTLE, SPRAY	2021-06-28
Primus Pharms	SERNIVO	betamethasone dipropionate	SPRAY;TOPICAL	208079	NDA	Primus Pharmaceuticals, Inc.	68040-714-28	1 BOTTLE, SPRAY in 1 CARTON (68040-714-28) / 120 g in 1 BOTTLE, SPRAY	2021-06-28

Suppliers and packagers for sernivo

Last updated: May 31, 2026

Sernivo (s) Pharmaceutical Supply Chain: What Suppliers Make It, What Ingredients They Provide, and Who Can Supply Alternatives?

Executive summary: Sernivo is a prescription topical corticosteroid brand. The supplier base for Sernivo depends on (1) the drug substance source, (2) the formulation and finished-dose manufacturing site, and (3) the packaging and logistics providers. A complete, actionable supplier map requires the specific Sernivo product strength, dosage form, and the exact FDA label/Orange Book listing tied to the marketed lot configuration; without those identifiers, supplier lists cannot be stated with accuracy.

What suppliers provide Sernivo active ingredient and drug substance?

Featured snippet: The drug-substance supplier for Sernivo is determined by the manufacturer listed on the FDA label and the Orange Book “Applicant/Manufacturer” fields for the specific strength and dosage form.

Which ingredient is supplied for Sernivo?

Sernivo is a topical corticosteroid. The drug substance supplier is the company manufacturing the active pharmaceutical ingredient (API) used to produce the finished cream/gel/solution type for the labeled strength.

What to extract from FDA label/Orange Book to identify the drug-substance supplier?

• Label “Manufactured for” and “Distributed by” lines
• Orange Book “Applicant” and “Manufacturer”
• NDC-to-manufacturer linkages (each NDC can map to different manufacturing sites)

Who manufactures Sernivo finished dosage and packaging?

Featured snippet: The finished-dose manufacturer for Sernivo is the “Manufacturer” entity tied to the marketed NDC strength on FDA listings, with packaging performed either in the same facility or by a secondary packaging partner.

Finished-dose manufacturing categories

• Primary manufacturing (API-to-finished blend)
• Compounding and filling
• Secondary packaging (carton, unit label, cobranding)
• Warehousing and distribution under wholesaler agreements

Common packaging formats to map to suppliers

• Tube cartons with leaflet insert
• Unit-dose packs (if applicable to a specific NDC)
• External case/wholesaler pack configuration

What suppliers provide contract manufacturing services for topical corticosteroids like Sernivo?

Featured snippet: For topical corticosteroids, contract manufacturing is typically carried out by large sterile and non-sterile topical CDMOs with topical semi-solid capability, validated under cGMP and controlled by the branded labeler.

Topical semi-solid CDMO supply roles

• Semi-solid development and scale-up
• API blending and homogenization
• In-process controls and release testing
• Stability program execution and shelf-life support

How to identify whether Sernivo is CDMO-built

• Compare “Manufacturer” on FDA label vs brandholder internal sites
• Check site correspondence across NDCs
• Look for consistent manufacturing addresses across multiple package sizes

Which raw material suppliers support Sernivo excipients and formulation?

Featured snippet: Excipients for topical corticosteroids (emollients, surfactants, preservatives, solvents) are sourced through specialty chemical supply chains that match the formulation recipe used by the finished-dose manufacturer.

Excipients that drive supplier dependency

• Emollient base and solvent system
• Surfactant system
• Preservatives/antimicrobial agents (if used in the labeled formula)
• Viscosity and texture modifiers for semi-solid consistency

Why excipient suppliers matter for continuity

• Excipient shortage or re-specification can trigger:
  • manufacturing batch delays
  • stability protocol changes
  • reformulation if suppliers cannot meet specs

How does NDC strength affect which suppliers provide Sernivo?

Featured snippet: Sernivo NDC-level granularity determines the exact manufacturing site and sometimes changes the supplier for either the drug product or packaging.

Supply chain mapping by NDC

• Each NDC can correspond to a distinct:
  • manufacturing site
  • labeler/agent
  • pack configuration
  • release-testing location

What Orange Book status does Sernivo have, and does it affect supply sourcing?

Featured snippet: If Sernivo is listed in the FDA Orange Book for drug product protection, it may identify the branded applicant and listed manufacturers, which often correspond to the supply entities used at launch.

What to look for in Orange Book to identify key suppliers

• Listed drug name and dosage form
• Route of administration
• Applicant (brandholder)
• Patent/ exclusivity record tied to the drug product
• Manufacturer(s) by NDC listing

What risks exist for Sernivo supply continuity and supplier substitution?

Featured snippet: The primary risks are excipient supply constraints, contract manufacturing capacity limits, and packaging line lead-time.

Supplier substitution risk points

• API lot-to-lot impurity drift
• Preservative or solvent sourcing changes impacting stability
• Packaging material spec changes (tube coating, closure liner, label inks)

Regulatory triggers

• Changes can require:
  • comparability protocols
  • stability studies
  • prior FDA notification depending on CMC change category

How do Sernivo suppliers compare with generics and private-label equivalents?

Featured snippet: Generic or private-label suppliers usually differ at the finished-dose manufacturing stage, even when the same API supplier is used, because formulation and packaging are often executed under separate CMC control.

What to compare when evaluating supplier equivalence

• Manufacturing site address and operator
• Finished-dose composition controls
• Stability program and shelf-life labeling
• Packaging component specs and supplier certifications

Key Takeaways

• Sernivo supplier mapping must be anchored to the exact labeled NDC/strength and FDA listing fields to name the actual API and finished-dose manufacturing entities.
• The supplier set is segmented into API/drug substance, finished-dose manufacturing, and packaging/logistics.
• NDC-level differences can materially change the manufacturing site and the practical supplier roster.
• Supply continuity risk concentrates in excipients, capacity of topical semi-solid CDMOs, and packaging line throughput.

FAQs

1. How can I identify the exact manufacturer for a specific Sernivo NDC?
2. Do API suppliers change when Sernivo switches manufacturing sites across strengths?
3. What supplier constraints most commonly disrupt topical corticosteroid production?
4. How does packaging format affect which Sernivo suppliers are involved?
5. Can a generic of Sernivo use the same API supplier but different excipient and packaging suppliers?

References

1. FDA Orange Book: Therapeutic Equivalence Evaluations and U.S. Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA Prescribing Information (Labeling) for Sernivo (sernivo topical product), U.S. Food and Drug Administration.